Literature DB >> 28368448

Adrenal Mass: Insight Into Pathogenesis and a Common Link With Insulin Resistance.

Giovanna Muscogiuri1, Maria Cristina De Martino2, MariaRosaria Negri1, Claudia Pivonello2, Chiara Simeoli2, Francesco Orio3, Rosario Pivonello2, Annamaria Colao2.   

Abstract

Adrenal mass (AM) is a common incidental finding detected during radiological investigations with an estimated incidence of 4%. Subjects with AM do not show any physical signs of adrenal hormonal excess, although they are often insulin resistant. Interestingly, apparently nonfunctioning AMs are often associated with a high prevalence of insulin resistance (IR) and metabolic syndrome. However, it is unclear whether AM develops from a primary IR and compensatory hyperinsulinemia or whether IR is only secondary to the slight cortisol hypersecretion by AM. Further, the degree of IR has been directly reported to correlate to the size of AM, thus allowing one to hypothesize that compensatory hyperinsulinemia to IR could be mitogenic on the adrenal cortex acting through the activation of insulin and insulinlike growth factor 1 receptors. Thus, the aim of the present article is to review the current evidence on the link between AM and compensatory hyperinsulinemia to IR.
Copyright © 2017 Endocrine Society.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28368448     DOI: 10.1210/en.2016-1804

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  9 in total

Review 1.  Autophagy as an emerging target in cardiorenal metabolic disease: From pathophysiology to management.

Authors:  Yingmei Zhang; Adam T Whaley-Connell; James R Sowers; Jun Ren
Journal:  Pharmacol Ther       Date:  2018-06-22       Impact factor: 12.310

2.  Adrenal morphology and associated comorbidities in congenital adrenal hyperplasia.

Authors:  Diala El-Maouche; Fady Hannah-Shmouni; Ashwini Mallappa; Courtney J Hargreaves; Nilo A Avila; Deborah P Merke
Journal:  Clin Endocrinol (Oxf)       Date:  2019-05-07       Impact factor: 3.478

3.  Biochemical and clinical characteristics of patients with primary aldosteronism: Single centre experience.

Authors:  Nataša Vujačić; Ivan Paunović; Aleksandar Diklić; Vladan Živaljević; Nikola Slijepčević; Nevena Kalezić; Mirjana Stojković; Miloš Stojanović; Biljana Beleslin; Miloš Žarković; Jasmina Ćirić
Journal:  J Med Biochem       Date:  2020-01-23       Impact factor: 3.402

Review 4.  Metabolic Stress, Autophagy, and Cardiovascular Aging: from Pathophysiology to Therapeutics.

Authors:  Jun Ren; James R Sowers; Yingmei Zhang
Journal:  Trends Endocrinol Metab       Date:  2018-08-22       Impact factor: 12.015

Review 5.  The Role of Insulin Resistance/Hyperinsulinism on the Rising Trend of Thyroid and Adrenal Nodular Disease in the Current Environment.

Authors:  Agathocles Tsatsoulis
Journal:  J Clin Med       Date:  2018-02-26       Impact factor: 4.241

Review 6.  Pathophysiological Link between Insulin Resistance and Adrenal Incidentalomas.

Authors:  Jordan A Higgs; Alyssa P Quinn; Kevin D Seely; Zeke Richards; Shad P Mortensen; Cody S Crandall; Amanda E Brooks
Journal:  Int J Mol Sci       Date:  2022-04-14       Impact factor: 6.208

7.  Is there a role for the IGF system and epidermal growth factor (EGF) in the pathogenesis of adrenocortical adenomas? A preliminary case-control study.

Authors:  I Lazúrová; I Jochmanová; Š Sotak; I Špaková; M Mareková
Journal:  Physiol Res       Date:  2020-11-19       Impact factor: 1.881

8.  The prevalence and characteristics of non-functioning and autonomous cortisol secreting adrenal incidentaloma after patients' stratification by body mass index and age.

Authors:  Ana Podbregar; Andrej Janez; Katja Goricar; Mojca Jensterle
Journal:  BMC Endocr Disord       Date:  2020-07-31       Impact factor: 2.763

9.  Pleomorphic Leiomyosarcoma of the Adrenal Gland in a Young Woman: A Case Report and Review of the Literature.

Authors:  Yuanyuan Wang; Yongliang Teng; Shibo Na; Ye Yuan
Journal:  Onco Targets Ther       Date:  2020-05-26       Impact factor: 4.147

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.